WB-MRI might become the first choice in advanced disease, castration-resistant prostate cancer (CRPC), as PSMA-PET/CT might be confounded by androgen blockade (AB) treatments which induce short term upregulation of PSMA expression and long term downregulation of this expression, limiting the possibility of following metastatic prostate cancer lesions at this stage (67, 68). The gene discussed is FOLH1; the disease is prostate cancer.